The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

She explains how the company’s new corporate branding aims to underscore its commitment to trust and transparency in its partnerships with pharma.

Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate ...

This Nasdaq biotech in my Stocks and Shares ISA portfolio just got a shot in the arm. Here's why I'm almost past caring at this point. The post Up 14% yesterday, is it the end for this train wreck in ...

"I was shocked to see this, frankly," said Jordan Green, head of the Biomaterials and Drug Delivery Laboratory ... by ...

A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States—sending greater numbers of babies and toddlers to the hospital, recent data show.

The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, ...

The agency might dissuade patients from participating in a crucial part of our research-and-development system.

Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...